Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

A. Yu; I. Snowhite; F. Vendrame; M. Rosenzwajg; D. Klatzman; A. Pugliese; T. R. Malek

doi:10.1089/dia.2016.2507

Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

A. Yu, I. Snowhite, F. Vendrame, M. Rosenzwajg, D. Klatzman, A. Pugliese, T. R. Malek

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	S73
Journal	Diabetes Technology and Therapeutics
Volume	18
DOIs	https://doi.org/10.1089/dia.2016.2507
State	Published - Feb 2016

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology
Medical Laboratory Technology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/dia.2016.2507

Cite this

Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. / Yu, A.; Snowhite, I.; Vendrame, F.; Rosenzwajg, M.; Klatzman, D.; Pugliese, A.; Malek, T. R.

In: Diabetes Technology and Therapeutics, Vol. 18, 02.2016, p. S73.

Research output: Contribution to journal › Comment/debate › peer-review

@article{c1bfcf913bb946d6a0160431b5e6da05,

title = "Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes",

author = "A. Yu and I. Snowhite and F. Vendrame and M. Rosenzwajg and D. Klatzman and A. Pugliese and Malek, {T. R.}",

year = "2016",

month = feb,

doi = "10.1089/dia.2016.2507",

language = "English (US)",

volume = "18",

pages = "S73",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

AU - Yu, A.

AU - Snowhite, I.

AU - Vendrame, F.

AU - Rosenzwajg, M.

AU - Klatzman, D.

AU - Pugliese, A.

AU - Malek, T. R.

PY - 2016/2

Y1 - 2016/2

UR - http://www.scopus.com/inward/record.url?scp=84957628953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957628953&partnerID=8YFLogxK

U2 - 10.1089/dia.2016.2507

DO - 10.1089/dia.2016.2507

M3 - Comment/debate

AN - SCOPUS:84957628953

VL - 18

SP - S73

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

ER -

Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this